Form 4 Sarepta Therapeutics, For: Apr 20 Filed by: Kaye Edward M. MD

Go back to Form 4 Sarepta Therapeutics, For: Apr 20 Filed by: Kaye Edward M. MD

Sarepta Therapeutics (SRPT) Halted Ahead of FDA AdCom

April 25, 2016 7:02 AM EDT

Sarepta Therapeutics (NASDAQ: SRPT) has been halted ahead of today FDA AdCom to review the New Drug Application (NDA) for eteplirsen.

After plunging last Thursday on negative-biased FDA briefing documents, shares surged on Friday on positive draft questions.

... More